Edward A. Sausville, M.D., Ph.D. Professor of Medicine
Associate Director for Clinical Research,
UM Greenebaum Cancer Center
Department:
Greenebaum Cancer Center: Hematology/Oncology
Medicine: Hematology/Oncology
UMGCC Research Program:
Experimental Therapeutics Program
Education/Training:
College Degree:
Manhattan College, Bronx, NY
Medical Degree:
Albert Einstein College of Medicine, NY
Residency:
Brigham & Women's Hospital, Boston
Fellowship:
National Cancer Insitute, Clinical Oncology
Certification:
Internal Medicine; Medical Oncology
Contact
Information:
Mailing Address:
University of Maryland Greenebaum Cancer Center
22 S. Greene Street, Room S9D07
Baltimore, MD 21201
Email:
esausville@umm.edu
Phone:
410-328-7394
Fax:
410-328-6896
Research Interests:
Dr. Sausville's research interest is new drug development and bringing new medicines and therapies out of the laboratory to patientsÂ’ bedsides. The goal is to use our knowledge of biology to give the most appropriate new treatments to individual patients, while at the same time minimizing their exposure to agents that have a low probability of working for them.
One of the new drugs Dr. Sausville was instrumental in bringing to clinical study, in collaboration with Millennium Pharmaceuticals, was Velcade, the first of a new class of medicines called proteasome inhibitors that was approved last year by the U.S. Food and Drug Administration for treatment of multiple myeloma, a bone marrow cancer. The drug showed such promise in early trials that it received accelerated approval from the FDA and is now being studied for use in a wide variety of blood and solid cancers.
Publications:
Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA, Reed JC. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 2004, 5:25-35.
Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET, Giavazzi R. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther. 2004; 3111-21.
Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R,
Rubinstein L, Sausville EA, Vistica DT. Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1. J Urol.; 1:1688-97.
Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, Sausville EA, Sawai ET, Gutkind JS. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A. 2004;101(14):4821-6.
Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(Allylamino)-17 demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs. 2004 15:377-87.
Hwang K, Acharya MR, Sausville EA, Zhai S, Woo EW, Venitz J, Figg WD, Sparreboom A. Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804:289-94.
Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA. The hollow fibre model in cancer drug screening: the NCI experience. Eur J Cancer. 2004;10:821-6.
Hollingshead MG, Bonomi CA, Borgel SD, Carter JP, Shoemaker R, Melillo G, Sausville EA. A potential role for imaging technology in anticancer efficacy evaluations. Eur J Cancer. 2004 40:890-8.
Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther. 2004 3:715-25.
Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS. Persistent activation of the Akt pathway in head and neck squamous cellcarcinoma: a potential target for UCN-01. Clin Cancer Res. 2004;10:4029-37.
